NCS1

Across TCGA pan-cancer cohorts, NCS1 Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated NCS1 data layer compared with 26 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in thymoma (THYM), where higher NCS1 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated NCS1 expression acts as an unfavorable survival marker.

THYM, ESCA, and STAD are the cancer types where NCS1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
THYM	OS	Median	III,IV	0.103	0.944	<.001	42	view →
ESCA	OS	Median	II,III,IV	0.212	0.686	.008	30	view →
STAD	OS	Median	II,III,IV	0.183	0.677	.004	24	view →
LUAD	OS	Median	III,IV	0.223	0.677	.006	15	view →
BLCA	DFS	Median	IV	0.025	0.476	<.001	6	view →
LIHC	OS	Median	All	0.167	0.688	.035	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

NCS1–THYM (OS)

Open the THYM breakdown →